RKDA

+ Watchlist + Portfolio

Arcadia Biosciences, Inc.

Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.28
52-Week Range: $0.22 – $6.71
Market Cap: $694.33K
P/E (TTM): —
EPS (TTM): -4.55
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.99
PEG Ratio: —
Return on Equity: -430.93%
Return on Assets: -34.76%
Gross Margin: 34.60%
Operating Margin: -34.37%
Profit Margin: -234.53%
Current Ratio: 3.49
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-868.50K
Revenue Growth: -0.80%
Earnings Growth: —
Enterprise Value: $-3.48M

RKDA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$7.42M	$4.45M	$5.04M	$4.86M
Cost of Revenue	$6.10M	$2.17M	$2.96M	$3.10M
Gross Profit	$1.32M	$2.28M	$2.08M	$1.76M
Research & Development	$1.51M	$64.00K	$53.00K	$9.00K
Selling, General & Admin	$15.04M	$8.23M	$9.64M	$7.00M
Operating Expenses	$16.55M	$8.30M	$9.69M	$11.76M
Operating Income	-$15.23M	-$6.02M	-$7.61M	-$9.99M
EBITDA	-$14.75M	-$5.73M	-$7.50M	-$9.96M
Pretax Income	-$10.81M	-$5.32M	-$4.31M	-$2.33M
Income Tax	$14.00K	$8.00K	$8.00K	$8.00K
Net Income	-$15.38M	-$13.98M	-$7.04M	-$2.34M
Diluted EPS	-25.65	-11.29	-5.17	-1.71
Diluted Shares	599389	1.24M	1.36M	1.37M

RKDA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$20.64M	$6.52M	$4.24M	$259.00K
Receivables	$1.22M	$506.00K	$3.07M	$425.00K
Inventory	$2.32M	$837.00K	$904.00K	$1.21M
Current Assets	$25.40M	$14.97M	$9.24M	$6.36M
Total Assets	$28.92M	$19.70M	$13.52M	$6.55M
Current Liabilities	$4.21M	$3.59M	$2.56M	$2.06M
Total Debt	$2.02M	$1.01M	$155.00K	$0.00
Total Liabilities	$8.02M	$7.00M	$7.29M	$2.41M
Retained Earnings	-$257.86M	-$271.84M	-$278.88M	-$281.22M
Shareholders' Equity	$21.03M	$12.84M	$6.22M	$4.14M
Working Capital	$21.19M	$11.38M	$6.68M	$4.30M

RKDA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$13.98M	-$15.29M	-$9.63M	-$4.74M
Capital Expenditure	-$72.00K	-$5.00K	-$16.00K	—
Free Cash Flow	-$14.05M	-$15.30M	-$9.64M	-$4.74M
Depreciation & Amortisation	$479.00K	$287.00K	$113.00K	$32.00K
Stock-Based Compensation	$1.11M	$717.00K	$512.00K	$234.00K
Investing Cash Flow	$1.42M	-$4.34M	$7.34M	$750.00K
Financing Cash Flow	$4.52M	$5.51M	$9.00K	$6.00K
Net Change in Cash	-$8.04M	-$14.13M	-$2.28M	-$3.98M

RKDA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$1.20M	$1.46M	$1.30M	$901.00K	$1.10M	$1.44M
Cost of Revenue	$682.00K	$824.00K	$884.00K	$709.00K	$700.00K	$812.00K
Gross Profit	$518.00K	$631.00K	$418.00K	$192.00K	$400.00K	$631.00K
Research & Development	$0.00	$9.00K	$0.00	$0.00	—	$0.00
Selling, General & Admin	$1.74M	$2.12M	$1.57M	$1.57M	$1.18M	$1.13M
Operating Expenses	$1.74M	$6.62M	$1.83M	$1.57M	$1.18M	$1.13M
Operating Income	-$1.22M	-$5.99M	-$1.41M	-$1.38M	-$779.00K	-$496.00K
EBITDA	-$1.21M	-$5.97M	-$1.41M	-$1.37M	-$771.00K	-$496.00K
Pretax Income	$2.60M	-$4.46M	$856.00K	-$1.33M	-$4.38M	-$6.27M
Net Income	$2.60M	-$4.46M	$856.00K	-$1.34M	-$4.38M	-$6.27M
Diluted EPS	1.90	-3.26	0.62	—	-2.11	-2.09
Diluted Shares	1.37M	1.37M	1.37M	—	2.08M	2.99M

RKDA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$3.16M	$1.38M	$1.12M	$259.00K	$954.00K	$4.18M
Receivables	$3.58M	$1.26M	$831.00K	$425.00K	$425.00K	$559.00K
Inventory	$1.28M	$1.49M	$1.46M	$1.21M	$840.00K	$930.00K
Current Assets	$8.85M	$7.58M	$8.39M	$6.36M	$5.17M	$5.74M
Total Assets	$12.99M	$7.79M	$8.58M	$6.55M	$5.32M	$5.89M
Current Liabilities	$2.22M	$1.84M	$2.29M	$2.06M	$1.36M	$1.65M
Total Debt	$21.00K	$11.00K	$0.00	$0.00	—	—
Total Liabilities	$4.08M	$3.25M	$3.14M	$2.41M	$2.44M	$5.26M
Retained Earnings	-$276.28M	-$280.74M	-$279.88M	-$281.22M	-$285.60M	-$291.87M
Shareholders' Equity	$8.90M	$4.53M	$5.44M	$4.14M	$2.88M	$633.00K
Working Capital	$6.63M	$5.74M	$6.10M	$4.30M	$3.80M	$4.09M

RKDA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$1.59M	-$2.03M	-$257.00K	-$861.00K	-$1.10M	-$319.00K
Free Cash Flow	-$1.59M	-$2.03M	-$257.00K	-$861.00K	-$1.10M	-$319.00K
Depreciation & Amortisation	$13.00K	$15.00K	$2.00K	$2.00K	$8.00K	$0.00
Stock-Based Compensation	$78.00K	$86.00K	$53.00K	$17.00K	$15.00K	$14.00K
Investing Cash Flow	$500.00K	$250.00K	$0.00	$0.00	$0.00	$0.00
Financing Cash Flow	$5.00K	$0.00	$1.00K	$0.00	$1.79M	$3.54M
Net Change in Cash	-$1.08M	-$1.78M	-$256.00K	-$861.00K	$695.00K	$3.22M

Market Snapshot

About

Arcadia Biosciences is an agricultural technology company focused on developing and commercializing crop productivity traits and nutritional oils. The company uses advanced breeding and biotechnology techniques to improve crop yield, quality, and environmental sustainability. Arcadia develops wheat, soybean, and canola varieties with enhanced nutritional profiles and agronomic performance.